Enfusion (ENFN) Scheduled to Post Earnings on Thursday

Enfusion (NYSE:ENFN) will issue its quarterly earnings data before the market opens on Thursday, May 9th. Analysts expect the company to announce earnings of $0.04 per share for the quarter. Enfusion has set its FY 2024 guidance at EPS.Persons interested in registering for the company’s earnings conference call can do so using this link.

Enfusion (NYSE:ENFN) last posted its quarterly earnings results on Tuesday, March 12th. The company reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.02). The business had revenue of $46.49 million during the quarter, compared to analyst estimates of $45.56 million. Enfusion had a net margin of 3.45% and a return on equity of 10.30%. On average, analysts expect Enfusion to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Enfusion Price Performance

NYSE:ENFN opened at $9.73 on Wednesday. The company has a market cap of $1.25 billion, a PE ratio of 121.64, a PEG ratio of 2.79 and a beta of 0.97. Enfusion has a one year low of $7.37 and a one year high of $11.56. The firm has a 50-day moving average of $9.19 and a 200-day moving average of $9.16.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. The Goldman Sachs Group lowered Enfusion from a “neutral” rating to a “sell” rating and lowered their price target for the company from $9.00 to $8.00 in a research report on Wednesday, February 28th. Bank of America increased their price objective on Enfusion from $8.00 to $9.00 and gave the company an “underperform” rating in a report on Wednesday, March 13th. Finally, JPMorgan Chase & Co. downgraded shares of Enfusion from a “neutral” rating to an “underweight” rating and reduced their target price for the stock from $11.00 to $9.00 in a research note on Tuesday, January 30th. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $9.33.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.